In Vivo is part of the Informa Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Tanabe Research Laboratories USA Inc.

Division of Mitsubishi Chemical Holdings Corp.
www.trlusa.com

Latest From Tanabe Research Laboratories USA Inc.

Wanted: Orphan Drugs, Antivirals Dominate China's Latest Fast Track List

Half of the newly selected imported drugs slated for fast track review in China are rare disease treatments, followed by antiviral drugs for influenza and HIV, reflecting key medical needs in the country.

Rare Diseases Review Pathway

Deal Watch: NASH In The Hot Seat

Regeneron stayed busy during the past two weeks, collaborating and making an equity commitment to CRISPR gene-editing biotech Intellia and signing an immuno-oncology deal with MedImmune. Allergan bounced off the termination of its merger with Pfizer by partnering with Heptares in neurological disease.

BioPharmaceutical Deals

Deal Watch: Genzyme Validates Alnylam's Strategy By Partnering On Hemophilia Candidate

Astellas/Chromocell pain therapy collaboration centers on New Jersey biotech's platform technology, which may solve the problem of reproducing Nav1.7 receptors for in vitro assays. Xoma signs preclinical immuno-oncology partnership with Novartis, dimming the focus on Phase III flop for gevokizumab.

BioPharmaceutical Deals

Deal Watch: Roche Wins Potential Blockbuster Esbriet In $8.3B Buyout Of InterMune

While Valeant prepares for an October court date to resolve Allergan’s attempt to fend off its latest takeover attempt, the acquisitive Canadian specialty firm picked up some dermatology products from Valeo Pharma. Also this week, Cilag acquired Covagen and Vaccinogen raised $80 million for development of OncoVAX.

BioPharmaceutical Deals
See All

Company Information

Advertisement
Advertisement
UsernamePublicRestriction

Register